Whitehawk Therapeutics presented data showing that PTK7 protein expression remains stable in EGFR wild-type non-small cell lung cancer (NSCLC) patients after standard treatments like chemotherapy and immunotherapy. This stability supports PTK7 as a reliable target for their next-generation antibody drug conjugate (ADC), HWK-007, currently in Phase 1 trials. The findings suggest HWK-007 could be effective in patients who have undergone multiple prior therapies, expanding treatment options for advanced lung cancer. Further clinical evaluation of HWK-007 is ongoing.
XRP's recent price rebound did not follow the expected five-wave Elliott Wave pattern, instead showing a weaker three-wave recovery. Currently trading around $1.32, XRP is close to the 61.8% Fibonacci retracement level at $1.31, with several nearby s...
XRP has been trading within a range of approximately $1.25 to $1.60 for about 10 weeks, showing price compression after a significant 70% gain in August. Analyst ChartNerd highlights a parallel channel between the 20-week and 50-week moving averages,...
Initia's blockchain and rollups have been offline since Friday due to a security breach where an attacker exploited a MoveVM bug to mint and bridge out approximately $2.7 million in tokens, including AUSD, ETH, and USDC. The attacker used LayerZero a...
The ADA/USDT perpetual chart on Bybit reveals a rising trend with higher highs and lows since June 2026, with key support near $0.22. ADA reached a peak near $0.25 in August but recently fell below $0.20. Maintaining the $0.22 support level is crucia...
Chart analyst Albert Brown predicts a potential trend shift for XRP around July or August 2027 if the pattern of roughly yearlong price advances and declines continues. His analysis is based on historical price phases lasting about 12 to 14 months, t...
